Brown: Risk Weighti...
Health Care: Drugs
Immunogen Inc. (IMGN: NASDAQ)
$16.29 0.21 | 1.31%
05/17/13 - 04:00 PM ET
587.60K / 764.20K
Vol / Avg. Vol:16.09 / 16.08
Open / Prev. Close:15.97 - 16.50
Today's Range:10.85 - 18.10
52 Wk Range:26.12%
Performance YTD:TheStreet Rating:
Portfolios with IMGN
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorHot Biotech Stocks Traded b...
- ContributorStocks Rising On Unusual Vo...
- ContributorEarnings Short Squeeze Play...
- UserJKE 1
- UserWatch List - Healthcare / B...
- UserCR
- UserASCO 2010
- UserPART 7 JPMorgan 28th Annual...
- UserStockPot
Latest IMGN Headlines from TheStreet
- ImmunoGen Breaks Below 200-Day Moving Average - Notable For IMGN 04.18.13 | 04:04 pm
- 'Mad Money' Lightning Round: Buy, Buy, Buy Toll Brothers 04.17.13 | 06:04 am
- Cramer's 'Mad Money' Recap: Next Week's Game Plan 04.05.13 | 07:04 pm
- Cramer's Top Stock Picks: QQQ IMGN SGEN ONXX 04.05.13 | 06:04 am
- ImmunoGen CEO Confident After Strong Q1
04.02.13 | 03:04 pm - Cramer's 'Mad Money' Recap: Focus on Making Money 02.26.13 | 08:02 pm
- Cramer's 6 Stocks in 60 Seconds: IMGN ISRG AZO BMRN WEN CAT 02.22.13 | 10:02 am
- Analysts' Actions: AKS BBBY IMGN RIG LIFE 01.28.13 | 08:01 am
- 2013 FDA Drug Approval Decision Calendar 12.19.12 | 09:12 am
- 3 Stocks I Saw on TV 12.11.12 | 08:12 am
Press Releases for IMGN
- ImmunoGen, Inc. Announces Webcast Of Its Analyst And Investor Community Meeting On April 12, 2013 - Business Wire 03.12.13 | 06:03 am
- ImmunoGen, Inc. Announces FDA Approval Of Kadcyla (Ado-Trastuzumab Emtansine; Also Known As T-DM1) - Business Wire 02.22.13 | 09:02 am
- ImmunoGen, Inc. Attains Patient Enrollment Milestone In IMGN901 NORTH Trial - Business Wire 02.12.13 | 06:02 am
- ImmunoGen, Inc. Announces Webcast Of Presentations At Upcoming Investor Conferences - Business Wire 02.05.13 | 01:02 pm
- ImmunoGen, Inc. Reports Second Quarter Fiscal Year 2013 Financial Results And Provides Quarterly Update - Business Wire 01.25.13 | 06:01 am
- ImmunoGen, Inc. Announces Conference Call To Discuss Its Second Quarter Fiscal Year 2013 Financial Results - Business Wire 01.18.13 | 06:01 am
- ImmunoGen, Inc. Announces Webcast Of Presentation At The 31st Annual J.P. Morgan Healthcare Conference - Business Wire 01.02.13 | 06:01 am
- Amgen Takes Third License For Rights To Use ImmunoGen’s TAP Technology - Business Wire 12.19.12 | 06:12 am
- ImmunoGen, Inc. Announces IMGN901 Clinical Data Presented At ASH - Business Wire 12.10.12 | 04:12 pm
- ImmunoGen, Inc. Announces Webcast Of Presentation At The Oppenheimer 23rd Annual Healthcare Conference - Business Wire 12.06.12 | 06:12 am
Partner Headlines for IMGN
- Market Wrap for Friday, April 12: Stocks Record Modest Losses; Treasuries Surge and Precious Metals Plunge - Benzinga 04.12.13 | 04:04 pm
- Cree, Seagate, Sandisk: Why Richie Freeman Likes Them - Investor's Business Daily 04.02.13 | 06:04 pm
- Roche Breast Cancer Drug To Succeed Herceptin - Investor's Business Daily 02.22.13 | 04:02 pm
- Show Me The Money: ADC Revenue Payloads Miss The Mark - Seeking Alpha 11.26.12 | 09:11 am
- UPDATE: Credit Suisse Initiates Immunogen at Neutral on Valuation - Benzinga 11.13.12 | 01:11 pm
- It's All Bad News For ImmunoGen After 1Q13 Earnings Release - Benzinga 10.26.12 | 04:10 pm
- Positive Results on Roche Candidate - Analyst Blog - NASDAQ 08.27.12 | 08:08 pm
- What's Moving The Market Today - Seeking Alpha 08.03.12 | 09:08 am
- Armed Antibodies: The Latest Weapon In The War Against Cancer - Seeking Alpha 07.23.12 | 09:07 am
- Yahoo HACKED and 3 Morning Hot Stocks Driving the Market - Wall St. Cheat Sheet 07.12.12 | 01:07 pm
